CRI's new website that seeks to engage, educate, and empower patients and their loved ones to learn more about cancer immunotherapy as a treatment option across numerous tumor types.
Cancer patients, donors, scientists, and other supporters all stand behind the Cancer Research Institute. Read their stories and learn about what motivates each of us to keep fighting against cancer.
By running in a marathon or hosting a bake sale, you can make a real difference for our scientists in the fight against cancer and allow them to bring newer immunotherapies to more patients.
We gratefully accept donations made in memory or in honor of a loved one. Your gift will be acknowledged to whomever you specify.
Numerous challenges can slow progress in finding new immune-based cancer treatments. We're solving some of the biggest challenges, accelerating promising new immunotherapies for patients.
Curious about the latest developments in cancer immunotherapy research? Listen in as leading scientists discuss immune-based treatments across numerous cancer types in our free "Breakthroughs in Cancer Immunotherapy" webinar series.
When the Cancer Research Institute was founded in 1953, we knew then that immune-based treatments would transform cancer medicine. In more than six decades since, we've made numerous groundbreaking discoveries that have given more patients new hope today.
Welcome to the Cancer Research Institute blog. Here we share the latest updates on the field of cancer immunotherapy from CRI, including scientific breakthroughs, news stories, and program announcements. We invite your comments and encourage you to share these stories with your friends.
You can receive notifications of new posts by subscribing to our blog. Just click the RSS icon in the upper right corner.
October 9, 2015
Nivolumab, a PD-1 immunotherapy, is now approved as second-line therapy for the most common type of lung cancer.
obituary, scientific leadership
Since its founding, CRI has upheld the highest standards of fiscal responsibility and integrity, making sure your charitable investment is impactful in our efforts to conquer cancer with immunotherapy.
For the last 60 years, Cancer Research Institute scientists have studied how to harness the power of the immune system to fight cancer, which is now recognized as "Breakthrough of the Year" by Science magazine.
cancer immunotherapy, progress, scientific leadership
community fundraising, events
Coley's toxins, history
Battling acute lymphoblastic leukemia, 6-year-old Emily Whitehead was enrolled in a clinical trial testing a therapy created by CRI scientist Dr. Carl June.
clinical trials, emma whitehead, leukemia, patients, T cell therapy
awareness, cancer immunotherapy, charity, donate, givingtuesday
charity, donate, givingtuesday